LABETALOL HYDROCHLORIDE

Pre-Launch

labetalol hydrochloride

ANDAINJECTIONINJECTABLE

Lifecycle

Pre-Launch

Data completeness

2/8 — Basic

LABETALOL HYDROCHLORIDE (labetalol hydrochloride) by Bristol Myers Squibb is alpha1-adrenergic blocking and competitive beta-adrenergic blocking activity. Approved for severe hypertension, to lower blood pressure, hypertension.

Drug data last refreshed 1mo ago

Mechanism of Action

alpha1-adrenergic blocking and competitive beta-adrenergic blocking activity. In man, the ratio of alpha- to beta-blockade has been estimated to be approximately 1:7 following intravenous administration. Beta 2 -agonist activity has been demonstrated in animals with minimal beta 1 -agonist activity…

Indications (3)

severe hypertension to lower blood pressure

Worked on LABETALOL HYDROCHLORIDE at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.